Primary aldosteronism: Evolving concepts in diagnosis and treatment

Current Opinion in Endocrinology and Diabetes

Volumn 11, Issue 3, 2004, Pages 153-157

  Khan, Uzma ^a   Gomez Sanchez, Celso E ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Hyperaldosteronism; Hypertension; Hypokalemia

Indexed keywords

ALDOSTERONE; AMILORIDE; EPLERENONE; HYDROCHLOROTHIAZIDE; POTASSIUM ION; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG RECEPTOR BINDING; ESSENTIAL HYPERTENSION; HUMAN; HYPOKALEMIA; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; SCREENING TEST; VEIN CATHETERIZATION;

EID: 33747741042     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000136124.71531.42     Document Type: Review

References (41)

1. Lim PO, MacDonald TM: Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol (Oxf) 2003, 59:427-430. Critical review of primary aldosteronism in a hypertension clinic.
2. Lim P, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Human Hyper 2000, 14:311-315.
3. Veglio F, Morello F, Rabbia F, et al.: Recent advances in diagnosis and treatment of primary aldosteronism. Minerva Med 2003, 94:259-265. Excellent perspective of the diagnostic approach in an Italian Hypertension Center.
4. Stowasser M, Gordon RD, Gunasekera TG, et al.: High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003, 21:2149-2157. Excellent review of the diagnostic maneuvers.
5. Mulatero P, Stowasser M, Loh KC, et al.: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004, 89:1045-1050. Collection of experiences from five continents on the different diagnostic approaches to primary aldosteronism and the similarity of results.
6. Young WF Jr: Primary aldosteronism: management issues. Ann N Y Acad Sci 2002, 970:61-76.
7. Young WF Jr: Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003, 144:2208-2213. Update of the importance that the disease has acquired in recent years and a review of the Mayo Clinic experience.
8. Mosso L, Carvajal C, Gonzalez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165. Classification of patients according to hypertensive stage and prevalence of primary aldosteronism. Study dispels the idea that it is a rare disorder, especially in severe hypertensive cases.
9. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
10. Lifton RP, Dluhy RG, Powers M, et at.: A chimaeric 11β-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
11. Stowasser M, Gordon RD: Primary aldosteronism: from genesis to genetics. Trends Endocrinol Metab 2003, 14:310-317. Update of the familial forms of primary aldosteronism.
12. Pascoe L, Jeunemaitre X, Lebrethon MC, et al.: Glucocorticoid suppressible hyperaldosteronism and adrenal tumors occurring in a single french pedigree. J Clin Invest 1995, 96:2236-2246.
13. Mulatero P, di Cella SM, Williams TA, et al.: Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 2002, 87:3187-3191.
14. Litchfield WR, Anderson BF, Weiss RJ, et al.: lntracranial aneurysm and hemorrhagic stroke in Glucocorticoid-remediable Aldosteronism. Hyper 1998, 31:445-450.
15. Lafferty AR, Torpy DJ, Stowasser M, et al.: A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000, 37:831-835.
16. Weber KT: Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone. J Lab Clin Med 2003, 142:71-82. Review of new and seldom recognized actions of aldosterone that are emerging as of great importance in the production of pathological damage in target organs.
17. Rossi GP, Di Bello V, Ganzaroli C, et al.: Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002, 40:23-27.
18. Kozakova M, Buralli S, Palombo C, et at.: Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension 2003, 41:230-236. Further description of the pathological consequences of aldosterone excess on the heart.
19. Horton R, Biglieri EG: Effect of aldosterone on the metabolism of aldosterone. J Clin Endocr Metab 1962, 22:1187-1192.
20. Delva P, Lechi A: Intralymphocyte magnesium decrease in patients with primary aldosteronism. Possible links with cardiac remodelling. Magnes Res 2003, 16:206-209. Recognition that alterations in intracellular magnesium plays a significant role in the pathophysiological actions of aldosterone.
21. Stowasser M, Gordon RD: Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003, 17:591-605.
22. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112-117. Recognition that excess aldosterone might be associated with resistant hypertension and in some patients with sleep apnea.
23. Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
24. Bortolotto LA, Cesena FH, Jatene FB, Silva HB: Malignant hypertension and hypertensive encephalopathy in primary aldosteronism caused by adrenal adenoma. Arq Bras Cardiol 2003, 81:97-100, 193-106. Interesting case report.
25. Zelinka T, Strauch B, Pecen L, Widimsky J Jr: Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 2004, 18:107-111.
26. Abdelhamid S, Blomer R, Hommel G, et al.: Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens 2003, 16:522-530. Very important paper where studies further demonstrating that way potassium is routinely drawn and measured have a profound effect on the plasma levels and the impression of the frequency of hypokalemia. Also demonstrates that alternative measurements of aldosterone metabolites might be far more sensitive in the screening for patients with primary aldosteronism.
27. Mulatero P, Rabbia F, Milan A, et at.: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002, 40:897-902.
28. Tanabe A, Naruse M, Takagi S, et al.: Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003, 88:2489-2494.
29. Ulick S, Laragh JH, Lieberman S: The isolation of urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man. Trans Ass Am Phy 1958, 71:225-235.
30. Espiner EA, Ross DG, Yandle TG, et al.: Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 2003, 88:3637-3644. A good demonstration of prediction of surgically remedial primary aldosteronism. However, patients studied had overt hypokalemia and represent the most severely affected.
31. Yamada T, Ishibashi T, Saito H, et al.: Adrenal adenomas: relationship between histologic lipid-rich cells and CT attenuation number. Eur J Radiol 2003, 48:198-202. Good demonstration of the value of CT attenuation number.
32. Nishizawa K, Nakamura E, Kobayashi T, et al.: Successful treatment of primary aldosteronism due to computed tomography-negative microadenoma. Int J Urol 2003, 10:544-546. Very illustrative case reports.
33. Wheeler MH, Harris DA: Diagnosis and management of primary aldosteronism. World J Surg 2003, 27:627-631.
34. Young WF Jr: Primary aldosteronism treatment options. Growth Horm IGF Res 2003, 13(Suppl A):S102-S108.
35. Lumachi F, Marzola MC, Zucchetta P, et al.: Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI. Nucl Med Commun 2003, 24:683-688.
36. Nakahama H, Fukuchi K, Yoshihara F, et al.: Efficacy of screening for primary aldosteronism by adrenocortical scintigraphy without discontinuing antihypertensive medication. Am J Hypertens 2003, 16:725-728.
37. Harris DA, Au-Yong I, Basnyat PS, et al.: Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol 2003, 29:467-474. A good review of surgical approaches and management.
38. Neville AM, O'Hare MJ: The human adrenal cortex, pathology and biology. An integrated approach. Heidelberg: Springer-Verlag; 1982.
39. Rutherford JC, Taylor WL, Stowasser M, Gordon RD: Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg 1998, 22:1243-1245.
40. Lim PO, Young WF, MacDonald TM: A review of the medical treatment of primary aldosteronism. J Hypertens 2001, 19:353-361.
41. Futterman LG, Lemberg L: The resurrection of spironolactone on its golden anniversary. Am J Crit Care 2004, 13:162-165. Description of a new drug for the treatment of aldosterone disorders and its expanding role in other forms of cardiovascular disease.